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Introduction 
    Vitamin D insufficiency affects almost 50% of the population worldwide1.           
This pandemic of hypovitaminosis D can mainly be attributed to lifestyle and 
environmental factors that reduce exposure to sunlight, which is required for 
ultraviolet-B (UVB)-induced vitamin D production in the skin. Levels of UVB 
radiation diminish with increasing distance from the earth's equator, during the 
winter months, and as a result of air pollution. Black people absorb more UVB 
in the melanin of their skin than do white people and, therefore, require more 
sun exposure to produce same amounts of vitamin D2. Importantly, conditions 
associated with reduced UVB-induced vitamin D production, such as high 
latitude, industrialization, and dark skin, have all been associated with increased 
blood pressure values2. The logical hypothesis that high UVB-induced vitamin 
D production is associated with low blood pressure was confirmed by a small 
trial of 18 patients with untreated essential hypertension3. The researchers found 
that systolic and diastolic blood pressure values were reduced by 6 mmHg after 
6 weeks of UVB irradiation three times per week. UVB irradiation was also 
associated with a 162% rise in plasma 25-hydroxyvitamin D (25[OH]D) 
concentrations, but in hypertensive patients who received UVA irradiation, no 
significant change in 25(OH)D levels or blood pressure occurred3. 
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The high prevalence of vitamin D insufficiency is a particularly important 
public health issue because hypovitaminosis D is an independent risk factor for 
total mortality in the general population4. A meta-analysis published in 2007 
showed that vitamin D supplementation was associated with significantly 
reduced mortality.5 Furthermore, vitamin D insufficiency is associated with an 
increased risk of cardiovascular events, but whether this association reflects a 
causal relationship remains unclear6, 7, 8. The effect of vitamin D on blood 
pressure could be one of the potential mechanisms underlying the link between 
vitamin D and cardiovascular disease. In this Review, we will summarize the 
mechanisms that are presumed to underlie the relationship between vitamin D 
and arterial hypertension, and examine the clinical data for this association. 
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Review of literature 
Hypertension 
              Elevated arterial blood pressure is a major cause of premature vascular 
disease leading to cerebrovascular events, ischaemic heart disease and 
peripheral vascular disease. Blood pressure is a characteristic of each individual, 
like height and weight, with marked interindividual variation, and has a 
continuous (bell-shaped) distribution. The levels of blood pressure observed 
depend on the characteristics of the population studied , in particular, the age 
and ethnic background. 
Definition: 
        Hypertension is defined as elevated arterial pressure that place patients at 
increased risk for target organ damage. According to JNC-VII report  
hypertension is defined as one of the following; systolic blood pressure >140 
mmHg; diastolic blood pressure >90 mmHg and those taking antihypertensive 
medications. 
          Cardiac output and peripheral resistance are the two determinants of 
arterial pressure. Cardiac output is determined by stroke volume and heart rate; 
stroke volume is related to myocardial contractility and to the size of the 
vascular compartment. Peripheral resistance is determined by functional and 
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anatomic changes in small arteries (lumen diameter 100–400 µm) and 
arterioles9. 
Classification:  
         This classification equates with those of the European Society of 
Hypertension and the World Health Organization-International Society of 
Hypertension 10. 
Table: 1 
Category Systolic blood 
pressure (mmHg) 
Diastolic blood 
pressure (mmHg) 
Blood pressure 
Optimal < 120 < 80 
Normal < 130 < 85 
High normal 130-139 85-89 
Hypertension 
Grade 1 (mild) 140-159 90-99 
Grade 2 (moderate) 160-179 100-109 
Grade 3 (severe) ≥180 ≥110 
Isolated systolic hypertension 
Grade 1 140-159 < 90 
Grade 2 ≥160 < 90 
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Prevalence: 
      Mohan et al reported an age-adjusted prevalence of 14% in Chennai. Gupta 
et al reported its prevalence in 36% men and 37% women in Jaipur 
Diagnosis Percentage 
Essential hypertension 
Renal hypertension 
     Parenchymal 
     Renovascular 
Endocrine hypertension 
      Primary aldosteronism 
      Cushings syndrome 
      Pheochromocytoma 
     OCP induced 
Miscellaneous 
Coarctation of aorta, PAN,  neurogenic  
and drug induced 
 >95% 
 
  2-3% 
  1-2% 
 
  0.3% 
  <0.1% 
  <0.1% 
  2-3% 
 
  1% 
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The onset is usually between ages 25 and 55 years, it is uncommon before age 
20 years. No specific cause is known for >95% of hypertension and the 
condition is known as essential hypertension. Secondary hypertension 
constitutes only 2-5% of cases. 
 
Mechanism of hypertension: 
Intravascular Volume 
          Vascular volume is a primary determinant of arterial pressure over the 
long term. Although the extracellular fluid space is composed of vascular and 
interstitial spaces, in general, alterations in total extracellular fluid volume are 
associated with proportional changes of blood volume. Sodium is 
predominantly an extracellular ion and is a primary determinant of the 
extracellular fluid volume. When NaCl intake exceeds the capacity of the 
kidney to excrete sodium, vascular volume initially expands and cardiac output 
increases. However, many vascular beds (including kidney and brain) have the 
capacity to autoregulate blood flow, and if constant blood flow is to be 
maintained in the face of increased arterial pressure, resistance within that bed 
must increase. 
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The initial elevation of blood pressure in response to vascular volume 
expansion is related to an increase of cardiac output; however, over time, 
peripheral resistance increases and cardiac output reverts toward normal. The 
effect of sodium on blood pressure is related to the provision of sodium with 
chloride; non-chloride salts of sodium have little or no effect on blood pressure. 
As arterial pressure increases in response to a high NaCl intake, urinary sodium 
excretion increases and sodium balance is maintained at the expense of an 
increase in arterial pressure. The mechanism for this "pressure-natriuresis" 
phenomenon may involve a subtle increase of glomerular filtration rate, 
decreased absorbing capacity of the renal tubules, and possibly hormonal 
factors such as atrial natriuretic factor. In individuals with an impaired capacity 
to excrete sodium, greater increases of arterial pressure are required to achieve 
natriuresis and sodium balance. 
 
NaCl-dependent hypertension may be a consequence of a decreased capacity of 
the kidney to excrete sodium, due to 
• A decrease in the filtration surface by a congenital or acquired deficiency 
in nephron number or function11. 
• A resetting of pressure-natriuresis relatonship12. 
• An acquired inhibitor of the sodium pumps. 
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• Nephron heterogenecity-presence of a sub group of nephrons that is 
ischemic either from afferent arteriolar vasoconstriction or from an 
intrinsic narrowing of the lumen. 
 
 
Autonomic Nervous System 
The autonomic nervous system maintains cardiovascular homeostasis via 
pressure, volume, and chemoreceptor signals. Adrenergic reflexes modulate 
blood pressure over the short term, and adrenergic function, in concert with 
hormonal and volume-related factors, contributes to the long-term regulation of 
arterial pressure. The three endogenous catecholamines are norepinephrine, 
epinephrine, and dopamine. All three play important roles in tonic and phasic 
cardiovascular regulation. 
Several reflexes modulate blood pressure on a minute-to-minute basis. 
One arterial baroreflex is mediated by stretch-sensitive sensory nerve endings 
located in the carotid sinuses and the aortic arch. The rate of firing of these 
baroreceptors increases with arterial pressure, and the net effect is a decrease of 
sympathetic outflow, resulting in decreases of arterial pressure and heart rate. 
This is a primary mechanism for rapid buffering of acute fluctuations of arterial 
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pressure that may occur during postural changes, behavioural or physiologic 
stress, and changes in blood volume. However, the activity of the baroreflex 
declines or adapts to sustained increases of arterial pressure such that the 
baroreceptors are reset to higher pressures. Patients with autonomic neuropathy 
and impaired baroreflex function may have extremely labile blood pressures 
with difficult-to-control episodic blood pressure spikes.  
Pheochromocytoma is the most obvious example of hypertension related 
to increased catecholamine production, in this instance by a tumour. Blood 
pressure can be reduced by surgical excision of the tumour or by pharmacologic 
treatment with an α1 receptor antagonist or with an inhibitor of tyrosine 
hydroxylase, the rate-limiting step in catecholamine biosynthesis. Increased 
sympathetic activity may contribute to other forms of hypertension. Drugs that 
block the sympathetic nervous system are potent antihypertensive agents, 
indicating that the sympathetic nervous system plays a permissive, although 
perhaps not a causative, role in the maintenance of increased arterial pressure.  
 
Renin-Angiotensin-Aldosterone: 
        The renin-angiotensin-aldosterone system contributes to the regulation 
of arterial pressure primarily via the vasoconstrictor properties of angiotensin II 
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and the sodium-retaining properties of aldosterone. There are three primary 
stimuli for renin secretion: (1) decreased NaCl transport in the thick ascending 
limb of the loop of Henle (macula densa mechanism), (2) decreased pressure or 
stretch within the renal afferent arteriole (baroreceptor mechanism), and (3) 
sympathetic nervous system stimulation of renin-secreting cells via β1 
adrenoreceptors. Conversely, renin secretion is inhibited by increased NaCl 
transport in the thick ascending limb of the loop of Henle, by increased stretch 
within the renal afferent arteriole, and by β1 receptor blockade. In addition, 
renin secretion may be modulated by a number of humoral factors, including 
angiotensin II. Angiotensin II directly inhibits renin secretion due to angiotensin 
II type 1 receptors on juxtaglomerular cells, and renin secretion increases in 
response to pharmacologic blockade of either ACE or angiotensin II receptors. 
The sequence of changes in patients with renovascular hypertension starts 
with the release of increased amounts of renin when sufficient ischemia is 
induced to diminish pulse pressure against the juxtaglomerular cells in the renal 
afferent arterioles. A reduction in renal perfusion pressure by 50 percent leads 
to an immediate and persistent increase in renin secretion from the ischemic 
kidney, along with suppression of secretion from the contralateral one. With 
time, an expanded body fluid volume causes renin levels to fall but not to the 
low level expected from the elevated BP13. 
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VASCULAR: 
Radius and compliance of resistance arteries are also important 
determinants of arterial pressure. Resistance to flow varies inversely with the 
fourth power of the radius, and consequently small decreases in lumen size 
significantly increase resistance. In hypertensive patients, structural, 
mechanical, or functional changes may reduce lumen diameter of small arteries 
and arterioles. Remodelling refers to geometric alterations in the vessel wall 
without changing vessel volume.  
Hypertensive patients have stiffer arteries, and arteriosclerotic patients 
may have particularly high systolic blood pressures and wide pulse pressures as 
a consequence of decreased vascular compliance due to structural changes in the 
vascular wall. Recent evidence suggests that arterial stiffness has independent 
predictive value for cardiovascular events.  
Endothelial dysfunction: 
      Endothelium is now known to be the source of multiple relaxing and 
contracting substance of which nitric oxide is an important vasodilator. 
hypertensive patients have been shown to have impaired nitric oxide mediated 
vasodilatory response. 
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Hyperinsulinemia / insulin resistance: 
      An association between hypertension and hyperinsulinemia has been 
established not only in obese but also non obese hypertensive. The 
hyperinsulinemia of hypertension arises as a consequence of resistance to the 
effects of insulin on peripheral glucose utilization. Insulin has multiple pressor 
effects, including activation of sympathetic activity, trophic action on vascular 
hypertrophy and increased renal sodium absorption. Normally the pressor 
effects are counteracted by insulin mediated increased synthesis of nitric oxide 
leading to normalisation of pressor effect. 
Essential Hypertension 
Essential hypertension tends to be familial and is likely to be the 
consequence of an interaction between environmental and genetic factors. The 
prevalence of essential hypertension increases with age, and individuals with 
relatively high blood pressures at younger ages are at increased risk for the 
subsequent development of hypertension. It is likely that essential hypertension 
represents a spectrum of disorders with different underlying pathophysiologies. 
In the majority of patients with established hypertension, peripheral resistance is 
increased and cardiac output is normal or decreased; however, in younger 
patients with mild or labile hypertension, cardiac output may be increased and 
peripheral resistance may be normal.  
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When plasma renin activity (PRA) is plotted against 24-h sodium 
excretion, ~10–15% of hypertensive patients have high PRA and 25% have low 
PRA. High-renin patients may have a vasoconstrictor form of hypertension, 
whereas low-renin patients may have a volume-dependent hypertension. 
Inconsistent associations between plasma aldosterone and blood pressure have 
been described in patients with essential hypertension. The association between 
aldosterone and blood pressure is more striking in African Americans, and PRA 
tends to be low in hypertensive African Americans. This raises the possibility 
that subtle increases of aldosterone may contribute to hypertension in at least 
some groups of patients who do not have overt primary aldosteronism. 
Furthermore, spironolactone, an aldosterone antagonist, may be a particularly 
effective antihypertensive agent for some patients with essential hypertension, 
including some patients with "drug-resistant" hypertension. 
 
Pathologic Consequences of Hypertension: 
Hypertension is a risk factor for all clinical manifestations of 
atherosclerosis. It is an independent predisposing factor for heart failure, 
coronary artery disease, stroke, renal disease, and peripheral arterial disease 
(PAD). 
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Heart 
Heart disease is the most common cause of death in hypertensive patients. 
Hypertensive heart disease is the result of structural and functional adaptations 
leading to left ventricular hypertrophy, diastolic dysfunction, CHF, 
abnormalities of blood flow due to atherosclerotic coronary artery disease and 
microvascular disease, and cardiac arrhythmias.  
Both genetic and hemodynamic factors contribute to left ventricular 
hypertrophy. Clinically, left ventricular hypertrophy can be diagnosed by 
electrocardiogram, although echocardiography provides a more sensitive 
measure of left ventricular wall thickness. Individuals with left ventricular 
hypertrophy are at increased risk for CHD, stroke, CHF, and sudden death. 
Aggressive control of hypertension can regress or reverse left ventricular 
hypertrophy and reduce the risk of cardiovascular disease. It is not clear if 
different classes of antihypertensive agents have an added impact on reducing 
left ventricular mass, independent of their blood pressure–lowering effect.  
Brain 
Hypertension is an important risk factor for brain infarction and 
haemorrhage. Approximately 85% of strokes are due to infarction and the 
remainder are due to haemorrhage, either intracerebral haemorrhage or 
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subarachnoid haemorrhage. The incidence of stroke rises progressively with 
increasing blood pressure levels, particularly systolic blood pressure in 
individuals >65 years. Treatment of hypertension convincingly decreases the 
incidence of both ischemic and hemorrhagic strokes.  
Kidney 
Primary renal disease is the most common etiology of secondary 
hypertension. Conversely, hypertension is a risk factor for renal injury and 
ESRD. The increased risk associated with high blood pressure is graded, 
continuous, and present throughout the entire distribution of blood pressure 
above optimal. The atherosclerotic, hypertension-related vascular lesions in the 
kidney primarily affect the preglomerular arterioles, resulting in ischemic 
changes in the glomeruli and postglomerular structures. Glomerular injury may 
also be a consequence of direct damage to the glomerular capillaries due to 
glomerular hyperperfusion. Glomerular pathology progresses to 
glomerulosclerosis, and eventually the renal tubules may also become ischemic 
and gradually atrophic. The renal lesion associated with malignant hypertension 
consists of fibrinoid necrosis of the afferent arterioles, sometimes extending into 
the glomerulus, and may result in focal necrosis of the glomerular tuft. 
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Peripheral Arteries 
In addition to contributing to the pathogenesis of hypertension, blood 
vessels may be a target organ for atherosclerotic disease secondary to long-
standing elevated blood pressure. Hypertensive patients with arterial disease of 
the lower extremities are at increased risk for future cardiovascular disease. 
Although patients with stenotic lesions of the lower extremities may be 
asymptomatic, intermittent claudication is the classic symptom of PAD. The 
ankle-brachial index is a useful approach for evaluating PAD and is defined as 
the ratio of noninvasively assessed ankle to brachial (arm) systolic blood 
pressure. An ankle-brachial index < 0.90 is considered diagnostic of PAD and is 
associated with >50% stenosis in at least one major lower limb vessel. Several 
studies suggest that an ankle-brachial index < 0.80 is associated with elevated 
blood pressure, particularly systolic blood pressure.  
 
VITAMIN D 
Vitamin D is the name of a group fat-soluble compounds that are 
essential for maintaining the appropriate mineral balance in the body. Vitamin 
D, called the most important vitamin, was discovered 1922 and at the time was 
primarily associated with bone health. The chemical structures of the D 
vitamins were determined in the 1930s by Professor Adolf Windaus’s 
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laboratory at the University of Göttingen in Germany and in 1971 Anthony W. 
Norman at the University of California, discovered the 1,25-dihydroxyvitamin 
D, the active form of vitamin D hormone. 
                  Vitamin D belongs to a group of several related sterols, with the two 
most important being D2 (ergocalciferol) and D3 (cholecalciferol) (Figure 1). 
The two forms differ chemically only in their side-chain structure, vitamin D2 
has a side chain that contains a double bond between carbon 22 and carbon 23 
and a carbon 24 methyl group14,15.  
 
 
Figure 1.  
a) D2 (ergocalciferol)  
b) D3 (cholecalciferol) 
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 UVB-INDUCED VITAMIN D  
 SUNLIGHT EXPOSURE  
Sunlight is composed of radiation of varying wavelengths, ranging from 
the infrared long wavelength light to the ultraviolet short wavelength light 
(UV). UV light is further divided into UVA (315 nm-400 nm) and the shorter 
wavelength UVB radiation. UVB causes sunburns, but it also initiates Vitamin-
D production in the skin. The 7-dehydrocholesterol (pro-vitamin D), a 
cutaneous membrane lipid, absorbs UVB radiation between wavelengths of 280 
and 315 nm and will thereby be converted into pre-vitamin D3 (pre-
cholecalciferol). Pre-vitamin D3 will isomerize into vitamin D3 
(cholecalciferol) . Vitamin D3 is transported to the liver by binding to VDBP. In 
elderly, the production capacity of vitamin D is lowered because of atrophy of 
the skin due to lower amount of membrane lipids 16. 
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 SKIN TYPE  
Larger amounts of the pigment melanin in the epidermal layer result in 
darker skin and decrease the capacity of the skin to produce vitamin D from 
UVB radiation 17. Reports consistently indicate lower circulating 25(OH)D 
levels in black persons compared with Caucasians. However it is not clear 
whether lower levels of 25(OH)D in persons with dark skin cause health 
concerns. 
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AGE  
Elderly people in Europe, especially nursing home residents, often suffer 
from vitamin D insufficiency. Aging decreases the amount of 7-
dehydrocholesterol produced in the skin by as much as 75% by the age of 70 
years. Therefore, a 70 year old person has approximately 25% of the capacity to 
produce cholecalciferol compared with a healthy young adult 18. However the 
skin has such a large capacity to make vitamin D that even elderly exposed to 
sunlight can achieve increased circulating concentrations of 25(OH)D. 
 
OBESITY  
                                             Obese individuals have been shown to have low 
circulating 25(OH)D concentrations 19,20. Since vitamin D is a fat soluble 
vitamin and is readily stored in adipose tissue, it could be sequestered in the 
larger body pool of fat of obese individuals. Researchers have observed that 
circulating 25(OH)D concentrations increased in both obese and lean subjects 
after exposure to an identical quantity of UVB radiation21. Obese subjects has a 
larger body surface area of exposure and would be expected to produce more 
pre-vitamin D which would result in higher circulating 25(OH)D 
concentrations, than would the lean subjects.  
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                                 However, the increase was less than half in the obese 
subjects than in the lean, one day after exposure. This indicates that the 
subcutaneous fat, which stores vitamin D, sequestered more of the cutaneous 
synthesized vitamin D in the obese than in the lean subjects since there was 
more fat available for this process. It has been suggested that obese individuals 
may avoid exposure to solar UV radiation, which is crucial for the cutaneous 
synthesis of vitamin22. 
 
 
SOURCES 
 
                                      Vitamin D is unique because it is derived from sunlight 
and foods. Vitamin D occurs only in foods of animal origin.  Liver, egg yolk, 
butter, and cheese, and some species of fish contain useful amounts. Fish liver 
oils although not considered to be a food are the richest source of vitamin D. 
Human milk has recently  been shown to contain considerable amounts of water 
soluble vitamin D sulphate . Other sources of vitamin D are foods artificially 
fortified with vitamin D, such as milk, margarine, vanaspathi, and infant 
foods23. 
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DIETARY SOURCES OF VITAMIN D 
 µg/per 100g  µg/per 100g 
 
BUTTER 
 
 
EGGS 
 
MILK 
 
 
FISH FAT 
 
0.5-1.5 
 
 
1.25-1.5 
 
0.1 
 
 
5-30 
 
SHARK LIVER 
OIL 
 
COD LIVER OIL 
 
HALIBUT 
LIVER OIL 
 
30-100 
 
 
200-750 
 
 
500-10,000 
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GENETIC FACTORS  
Worldwide variations observed in circulating 25(OH)D concentrations 
may be due to common environmental factors such as UVB exposure dependent 
on latitude, season, clothing related to religious or cultural issues, as well as 
diet, and fortified-food strategies. Individual behavioural aspects such as 
clothing, use of sunscreen, time spent outdoors, sun habits, use of vitamin D 
supplements, skin sensitivity and the body fatness may also affect 
concentrations 24,25,26. Individual and environmental factors as well as genetic 
predisposition could play a role in the possibility to increase circulating 
25(OH)D levels. It is very important to further investigate the influence of 
genetic factors as compared with environmental factors on the vitamin D status. 
There are conflicting results regarding the genetic effect on summer and winter 
vitamin D status27,28. Vitamin D concentrations could be influenced by genetic 
factors in several potential ways. First is individual skin sensitivity and the 
capacity to produce vitamin D3, which includes the presence of the substrate 7-
dehydrocholesterol, the ability to convert 7-dehydrocholesterol to pre-vitamin 
D3 and further to vitamin D3. Second is the catabolism of formed pre-vitamin 
D3 into inactive vitamin D photoproducts such as lumisterol, tachysterol, 
suprasterols, and toxisterols. Third alternative genetic factor that may influence 
circulating 25(OH)D concentrations involves the vitamin D-binding protein 
(VDBP), which binds to vitamin D and its plasma metabolites and transports 
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them to target tissue29,30. Another process possibly influenced by genes is the 
hydroxylation of 25(OH)D to 1,25(OH)D by the enzyme 1,α-hydroxylase, 
particularly since 1,α-hydroxylase has been found in almost all cells and tissues 
31,32. 
THE ROLE OF VITAMIN D IN HEALTH  
In epidemiological studies vitamin D has been suggested to prevent 
several diseases. While it may not be a cure, a deficiency in vitamin D may be a 
risk factor for disease and therefore the increase in the number of individuals 
being diagnosed with vitamin D deficiency can be a public health problem.  
 
 BONE HEALTH  
The steroid hormone 1,25(OH)D gets transported by the VDBP to its 
target organs which control calcium and phosphorus metabolism. The 
interaction between 1,25(OH)D and its nuclear vitamin D receptor (VDR) in the 
small intestine increases the expression of calcium channels and calcium 
binding protein which results in increased absorption of calcium from the diet 
33,34. Vitamin D sufficiency will activate the calcium transport system and 
permits dietary calcium to be absorbed into the bloodstream. A low dietary 
intake of calcium will increase the secretion of parathyroid hormone (PTH), 
which improves renal production of 1,25(OH)D, thereby increasing the 
efficiency of calcium absorption. 1,25(OH)D will also increase the absorption 
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of dietary phosphorus. Approximately 55–70% of dietary phosphorus is 
passively absorbed. Vitamin D increases phosphorus absorption by an 
additional 20% so that approximately 80% of dietary phosphorus is absorbed . 
The main function of vitamin D is to uphold serum calcium within a satisfactory 
range for the maintenance of neuromuscular function, signal transduction and a 
wide variety of metabolic processes35. In infants and children, heavy vitamin D 
deficiency results in failure of bone mineralization. Rapidly growing bones are 
at the greatest risk to be affected by rickets. The growth plates of bones 
continue to broaden, but in the absence of satisfactory mineralization, arms and 
legs become deformed. In infants, the result of rickets might be delayed closure 
of the fontanels in the skull, and the rib cage may become deformed because of 
the pulling action of the diaphragm. Although vitamin D fortification of foods 
has led to decrease in vitamin D deficiency in most developed countries, 
nutritional rickets is still being described in places all over the world 36,37. Adult 
bones that are no longer growing are still in a constant state of turnover, or 
“remodelling”. The collagenous bone matrix is maintained but bone mineral is 
gradually lost, causing bone pain and osteomalacia (soft bones) in adults with 
severe vitamin D deficiency. Although osteoporosis is a multifactorial disease, 
vitamin D insufficiency can be a very important contributing factor.   
 CANCER  
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Two characteristics of cancer cells are the lack of cell differentiation and 
rapid uncontrolled growth or proliferation. Most malignant tumors, including 
breast, lung, skin, colon, and bone tumors, have been discovered to contain 
VDR. The biologically active form of vitamin D, 1,25(OH)D and its analogs, 
have been found to induce cell differentiation and suppress proliferation of a 
number of cancerous and noncancerous cell types preserved in cell culture38. 
The worldwide distribution of for example colon cancer mortality shows a 
similar pattern as the historical geographic distribution of rickets39,40, providing 
some evidence that low sunlight exposure and vitamin D status might be related 
to an increased risk of colon cancer. More recent studies have reported that 
greater vitamin D intakes and circulating 25(OH)D concentrations are 
associated with decreased colorectal cancer risk. A five-year prospective study 
with more than 120 000 participants, reported that men with the highest vitamin 
D intake had a 29% decreased risk of colorectal cancer compared to men with 
the lowest vitamin D intakes 41. Another study with pooled, dose-response 
analysis of two case-control studies showed that women with breast cancer had 
significantly lower circulating 25(OH)D concentrations compared to the 
controls 42,43. Another study reported that women with circulating 25(OH)D 
concentration of ~130 nmol/L (52 ng/ml) had a 50% lower risk of developing 
breast cancer compared to women with 25(OH) D levels lower than 32.5 
nmol/L (13 ng/mL) . In a prospective study from Finland, Norway and Sweden, 
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a U-shaped relationship between serum 25(OH) D levels and prostate cancer  
risk was observed; circulating 25(OH)D concentrations of 19 nmol/L (7.6 
ng/ml) or lower and 80 nmol/L (32 ng/ml) or higher were associated with higher 
prostate cancer risk 44. Epidemiological studies have demonstrated an 
association between risk factors for prostate cancer and environmental 
conditions that can result in low vitamin D levels . There is a higher incidence 
of prostate cancer in African American men than in white American men, and 
the higher amount of melanin content in dark skin is known to reduce the 
efficiency of vitamin D synthesis 45.  
 
 AUTOIMMUNE DISEASES  
Data from human, animal, and in vitro experiments are suggesting that 
vitamin D might play an important part in the autoimmunity 46. There is 
accumulating evidence of vitamin D status as a potential environmental factor 
affecting autoimmune disease prevalence. An unhealthy vitamin D status has 
been implicated in the etiology of autoimmune diseases such as multiple 
sclerosis (MS) 47, rheumatoid arthritis (RA) 48, diabetes mellitus (DM) 49, and 
inflammatory bowel disease (IBD) . It is clear that both genetic and 
environmental factors affect the prevalence of above mentioned diseases. 
Vitamin D has been involved as a factor in many different autoimmune diseases 
which suggest that vitamin D might be an environmental factor that normally 
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participates in the control of the “self-tolerance” where the body does not mount 
an immune response to self-antigens. In addition, there may be a greater vitamin 
D requirement for patients at risk for developing or already having an 
autoimmune disease. The ideal amount of vitamin D to support the immune 
system may be different from the amount of vitamin D that is required for 
prevention of other diseases or to maintain calcium homeostasis . In addition to 
the data that indicate vitamin D status as an environmental factor that affects 
autoimmune disease prevalence, patients with autoimmune diseases also have 
been shown to express genetic polymorphisms for vitamin D regulatory genes. 
Polymorphisms in the VDR have been associated with increased susceptibility 
to MS 50, RA51, Dm52 and IBD 53. 
 
 Cardiovascular diseases  
The etiology of cardiovascular diseases (CVD) is still not totally 
understood. Mounting evidence suggests that vitamin D deficiency is associated 
with increased risk of cardiovascular diseases, but the underlying mechanisms 
remain to be explored in detail54 . Data from epidemiologic studies indicate that 
geographic latitude, altitude, season, and the place of living are all associated 
with CVD mortality55. There have been no adequate explanations offered for 
these coincidences. However, these environmental factors all share the property 
of influencing UVB exposure and therefore also human vitamin D status. The 
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vitamin D hypothesis regarding the etiology of CVD is in line with the higher 
prevalence of CVD in obese and elderly individuals and the low prevalence of 
CVD in physically active individuals, since vitamin D status is inversely 
associated to body weight 56 and age57, 58 and is positively associated to the level 
of physical activity . Also ethnicity influence vitamin D status and CVD risk 59. 
A systematic review show a statistically significantly inverse association 
between circulating 25(OH)D concentrations and cardiovascular disease among 
nine prospective studies regarding both CVD incidence and mortality, however 
there was a heterogeneity among the studies .  
There are a number of mechanisms that might clarify the association between 
vitamin D status and CVD, among them an association of vitamin D with 
inflammatory markers. Activity of 1α-hydroxylase is regulated by several 
inflammatory and hormonal mechanisms which suppresses 1α-hydroxylase 
activity . 1α-hydroxylation of 25(OH)D occur in most cells and tissues in the 
body, nevertheless circulating concentrations of 1,25(OH)D are mainly 
predicted by renal 1α-hydroxylase activity. The VDR is nearly ubiquitously 
expressed, and almost all cells respond to 1,25(OH)D exposure; about 5% of the 
human genome is regulated, directly and/or indirectly, by the vitamin D 
endocrine system . This suggests a widespread function and possible causal 
relationship between vitamin D deficiency and cardiovascular risk.  
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VITAMIN D AND BLOOD PRESSURE  
 MECHANISMS  
 THE RENIN-ANGIOTENSIN SYSTEM (RAS) 
                  Vitamin D is a negative regulator of the hormone renin, the essential 
hormone of the RAS60. Increased activation of the RAS, which is a main 
regulator of electrolyte and volume homeostasis, contributes to the development 
of arterial hypertension 61. Mechanistic insights have been gained by studying 
mice deficient for the vitamin D receptor, which develop hypertension and 
adverse cardiac remodelling mediated via the renin-angiotensin system 62. 
Increased activation of the renin–angiotensin–aldosterone system (RAAS), 
which is a main regulator of electrolyte and volume homeostasis, contributes to 
the development of arterial hypertension. Renin is mainly synthesized by the 
juxtaglomerular cells of the kidney and stimulates the production of angiotensin 
II and of aldosterone, which increase blood pressure directly by 
vasoconstriction and indirectly by salt and water retention and other 
mechanisms. Inappropriate, increased activation of the RAAS has been reported 
in VDR and 1 -hydroxylase knockout mice, although it should be 
acknowledged that the increase in renin activity did not achieve statistical 
significance. Importantly, VDR and 1 -hydroxylase knockout mice developed 
arterial hypertension and myocardial hypertrophy, which were present even 
after normalization of calcium homeostasis; however, blocking of the RAAS 
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system with angiotensin-converting-enzyme inhibitors normalized blood 
pressure and cardiac abnormalities, Furthermore, increased RAAS activation, 
arterial hypertension, and myocardial abnormalities could be successfully 
treated with 1,25(OH)2D in 1 -hydroxylase knockout mice. The molecular 
effects of vitamin D on the RAAS have been clarified by the finding that 
liganded VDR suppresses renin expression by binding to the transcription factor 
cAMP-response element-binding protein (CREB). As a result, stimulation of 
renin transcription is inhibited because CREB is no longer able to stimulate 
renin transcription by binding to cAMP response elements in the promoter 
region of the renin gene. In patients with arterial hypertension, renin activity has 
been inversely associated with 1,25(OH)2D levels.  
 EFFECTS ON CELLS OF THE VESSEL WALL  
       Vitamin D and its equivalents cause several effects on the cells of the 
vessel wall, which include vascular smooth muscle cells, endothelial cells and 
macrophages, all of them expressing the VDR as well as 1α-hydroxylase25. 
Vitamin D’s effect on vascular smooth muscle cells is complex and is also 
modulated by other hormones, such as parathyroid hormone and estrogenic 
compounds, which up-regulate 1α-hydroxylase in these cells63. 1,25(OH)D is 
thought to protect against vascular problems by decreasing endothelial 
adherence molecules, by increasing the activity of endothelial nitric oxide 
synthase, and through its anti-inflammatory properties64. 
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AIMS AND OBJECTIVES 
 
1. To study the level of vitamin- D in patients with essential hypertension. 
 
2. To identify whether any association exists between age , sex, body mass 
index, diabetes, and target organ   damage and the presence of decreased 
level of vitamin -D. 
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MATERIALS AND METHODS 
Setting Government Rajaji hospital and Madurai 
medical college, Madurai. 
Collaborative department Department of biochemistry, Madurai 
medical college, Madurai. 
Study design Cross sectional study 
Period of study 1-4-2011 to 30-09-2011. 
Sample size 40 cases and 20 controls 
Ethical committee approval The present project was approved by the 
ethical committee 
Conflict of interest 
Financial support 
Nil  
Nil  
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INCLUSION CRITERIA: 
• Patients with essential hypertension 
•  Patients whose age were above 25 years, 
• Both sexes were included. 
EXCLUSION CRITERIA: 
• Individuals below 25 years were excluded 
• Patients with renal failure 
• Pregnancy 
• Patients with secondary hypertension 
• Patients who were on calcium or vitamin –D supplements 
• Patients on long term diuretics.  
•  Patients receiving any other vitamin D supplementation. 
CONTROLS:    
         Subjects whose age were above 25 years and had normal blood 
pressure and who met the above exclusion criteria. 
Consent 
               The study group thus identified by the above criteria (inclusion and 
exclusion criteria) was first instructed about the nature of the study. Willing 
40 
 
participants were taken up after getting a written informed consent from 
them. 
Materials  
         Around 40 cases and 20 controls meeting the above said criteria and who 
gave written informed consent were taken as subjects for the study. 
 
LIMITATIONS  
1.  In this study, both newly detected as well as known cases of essential 
hypertension on treatment were included in the study. 
2. The study population included patients with essential hypertension both 
with and without target organ damage and other cardiovascular risk factor 
but without renal failure. 
3. The study was only an observational study of hypovitaminosis-d in 
hypertensive patients and controls were included. 
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METHODS 
  Selected socio-demographic, clinical and laboratory data were elicited 
from the patients and recorded in a profoma . (annexure – I) 
 
I. SOCIO-DEMOGRAPHIC DATA 
• Age 
• Sex 
II. CLINICAL DATA 
• Body mass index 
• Systolic and diastolic blood pressure 
• Cardiovascular risk factors 
• Clinical examination 
 
III. LABORATORY DATA 
• Blood urea : Estimation done manually by using diacetyl 
monoxime technique 
• Serum Creatinine : Estimation was done using COBAS 
autoanalyser. 
• Serum albumin : Bromo cresol green (end point assay) 
• Serum calcium : Arsenazo III method. 
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• Serum phosphorus : UV Molybdate (end point assay). 
• Serum uric acid : Acid enzymatic method. 
• Vitamin D : Enzyme immune assay 
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STATISTICAL TOOLS  
The information collected regarding all the selected cases were recorded 
in a Master Chart. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre for 
Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-square  
test was used to test the significance of difference between quantitative 
variables and Yate’s chi square test for qualitative variables. A 'p' value less 
than 0.05 is taken to denote significant relationship. 
 
Definitions used in the present study 
• Essential hypertension 
        According to the JNC-VII report , hypertension is defined as systolic 
blood pressure of 140mm Hg and above and or diastolic  blood pressure 
of 90mmHg and above . In newly detected cases it was the mean of 3 
relaxed , seated right arm reading. The diagnosis that the hypertension is 
essential and not secondary was made on the over all clinical impression 
only. Laboratory investigations to rule out secondary causes were not 
done in each case . 
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• HYPOVITAMINOSIS –D 
        Hypovitaminosis-D is defined in this study as serum level of                                                                          
Vitamin – D less than 37.5nmol/l 
• DIABETES MELLITUS 
• Already a known case of diabetes mellitus on treatment 
• Fasting plasma glucose > 126m g/dl 
• Two hour plasma glucose > 200mg/dl 
• Symptoms of diabetes plus random blood glucose > 200mg/dl 
• LEFT VENTRICULAR HYPERTROPHY 
        Based on electrocardiographic findings satisfying either sokolon-
lyon criteria or cornell voltage criteria . 
• HYPERTENSIVE  RETINOPATHY 
    Based on keith- wagner – baker grading 
    Grade I – attenuation of arteries 
    Grade II -  arterio-venous nipping 
   Grade III - with haemorrhage and exudates 
  Grade IV –  with papilledema. 
 
 
 
45 
 
 
RESULTS 
A : PROFILE OF CASES STUDIED 
TABLE 1: AGE DISTRIBUTION 
Age group Normotensive 
group 
Hypertensive 
group 
No % No % 
Upto 50 years - - 8 20 
51-60 years 8 40 12 30 
61-70 years 11 55 16 40 
> 70 years 1 5 4 10 
Total 20 100 40 100 
Range 54-71 years 31-77 years 
Mean 63.0 years 59.0 years 
SD 5.5 years 9.6 years 
‘p’ 0.133 
Not significant 
 
 The hypertensive group had an age of 59 +9.6 years and the normotensive 
group 63 +5.5 years. There was no statistically significant difference.  
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TABLE 2: SEX DISTRIBUTION 
 
Sex 
Normotensive 
cases 
Hypertensive 
Cases 
No % No % 
Male 14 70 29 72.5 
Female 6 30 11 27.5 
Total 20 100 40 100 
‘p’ 0.9193  
Not significant 
 
 The control group had 20 patients of which 14 were male and 6 were 
female , and 40 hypertensive patients were included of which 29 were male and 
11 were female. Sex distribution of the study group and control group did not 
have any significant difference ( p = 0.9193). 
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TABLE 3: PHYSIOLOGICAL VARIABLES 
Variable Normotensive  Hypertensive ‘p’ 
Mean SD Mean SD 
Height ( in cms) 166.1 5.9 163.1 6.4 0.1112  
Not significant 
Weight ( in kgs) 70.3 7.7 65.9 8.5 0.1052  
Not significant 
BMI 25.46 2.81 25.1 3.07 0.672 
Not significant 
 
 Height, weight and BMI of the normotensive and hypertensive cases 
studied did not have any significant difference ( p > 0.05). 
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PHYSIOLOGICAL VARIABLES 
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TABLE 4: BLOOD PRESSURE 
Blood pressure Normotensive  Hypertensive ‘p’ 
Mean SD Mean SD 
SBP  115 5.91 163.05 16.7 0.0001  
Significant 
DBP 75.0 5.1 95.95 9.33 0.0001  
Significant 
 
 Systolic and diastolic blood pressures of the normotensive groups (115 + 
5.91 and 75 +5.1) were significantly lower than those of the hypertensive group 
(163.05 ± 16.67and 95.95 + 9.33). 
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BLOOD PRESSURE IN HYPERTENSIVE AND NORMOTENSIVE 
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TABLE 5 : RISK FACTORS AND TARGET ORGAN DAMAGE 
 Factors Normotensive 
cases 
Hypertensive  
Cases 
‘p’ 
No % No % 
a) Smoking (among 
males) 
Yes 
No 
 
11 
3 
 
78.6 
21.4 
 
27 
2 
 
93.1 
6.9 
 
0.1858 
Not significant 
b) Echo 
 Normal 
 Abnormal  
 
20 
- 
 
100 
- 
 
21 
19 
 
52.5 
47.5 
 
0.0006  
Significant 
 c) DM 
Yes 
No 
 
6 
14 
 
30 
70 
 
13 
27 
 
32.5 
67.5 
 
0.9218 
Not significant 
 d) Retinopathy  
  I 
 II 
III 
IV 
Total 
 No 
 
- 
- 
- 
- 
Nil 
20 
 
- 
- 
- 
- 
Nil 
100 
 
6 
8 
7 
7 
28 
12 
 
15 
20 
17.5 
17.5 
70 
12 
 
 
 
0.0001  
Significant 
 e) ECG 
 LAD 
LAD, LYH 
 WNL 
 
1 
- 
19 
 
5 
- 
95 
 
4 
19 
17 
 
10 
47.5 
42.5 
 
0.0003  
Significant 
Percentage of abnormal values in Echo, ECG and Retinopathy were 
significantly higher in the hypertensive group ( p < 0.05). 
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                                    TARGET ORGAN DAMAGE 
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TABLE 6: VITAMIN D LEVELS 
 
Vitamin D level Normotensive 
Cases 
Hypertensive 
Cases 
No % No % 
Level – I  - (< 37.5 nmol L-1) 2 10 23 57.5 
Level II - (<37.5 – 49.9 nmol L-1) 4 20 3 7.5 
Level III - (50 – 74.9 nmol L-1) 10 50 8 20.0 
Level IV- (75 – 100 nmol L-1) 4 20 6 15.0 
Vit D ( in nmol L-1) 
Range 
Mean 
SD 
 
24.9 – 90 
62.3 
18.4 
 
20.8-88.9 
46.6 
20.6 
P 0.0072  
Significant 
 
 The mean Vit. D value in the normotensive cases was 62.3 nmol L-1. This 
was significantly higher than their mean values in hypertensive cases (46.6 
nmol L-1). This difference was statistically significant ( p = 0.0072). 
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B: RELATIONSHIP BETWEEN VIT D LEVELS AND OTHER 
VARIABLES IN HYPERTENSIVE CASES 
TABLE 7: VIT D LEVELS AND AGE 
Vit D Age in years 
Mean SD 
I 58.3 9.2 
II 64.7 8.6 
III 58.6 11.5 
IV 59.5 10.7 
‘p’ 0.7144  
Not significant 
 
 Vit D values and age of the patient did not have any statistically 
significant relationship ( p = 0.7144). 
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TABLE 8: VIT D LEVEL AND SEX 
Vit D level Sex 
Male ( 29) Female ( 11) 
No % No % 
I 17 58.6 6 54.5 
II 2 6.9 1 9.1 
III 6 20.7 2 18.2 
IV 4 13.8 2 18.2 
Vit D 
Range 
Mean 
SD 
 
20.8 – 88.9 
45.7 
21.5 
 
31.2 – 78.4 
49.0 
18.9 
‘p’ 0.2142  
Not significant 
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Vit D levels among males and females did not have any significant 
difference ( p > 0.05). 
TABLE 9: VIT D LEVEL AND PHYSIOLOGICAL PARAMETERS 
Vit D level Height  Weight BMI 
Mean SD Mean SD Mean SD 
I 162.3 6.6 67.6 8.5 25.69 2.99 
II 159.7 5.7 63.3 12.7 24.68 3.17 
III 163.1 7.2 6.3 5.8 23.77 2.8 
IV 161.5 6.4 64.7 10.0 24.83 3.84 
‘p’ 0.8982  
Not 
significant 
0.4115 
Not 
significant 
0.5131 
Not 
Significant 
 
 In the hypertensive cases, there was no significant relationship between 
Vit D levels and height, weight and BMI of the patients ( p > 0.05). 
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TABLE 10:VITAMIN D LEVELS AND OTHER QUANTITATIVE 
PARAMETERS 
Variable Value ( Mean +SD) for cases with Vit. D level ‘p’ 
I II III IV 
Urea 27.7 +7.2 23.3 +1.5 28.3 +7.4 29 +6.8 0.6582  
Not significant 
Corr. Ca 7.65 +0.44 7.58 +0.43 8.02 +0.33 8.5 +0.54 0.0061 
Significant 
Phosphate  3.97 +0.74 3.8 +1.37 3.86 +0.84 3.52 +0.51 0.5447  
Not significant 
Albumin  3.51 +0.43 3.73 +0.25 3.55 +0.31 3.4 +0.22 0.4713 
Not significant 
Sr. 
Creatinine 
1.2 +0.23 1.07 +0.21 1.16 +0.14 1.13 +0.12 0.7268  
Not significant 
There was significant association between Corr.Ca. and Vit. D levels in 
hypertensives  
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TABLE 11: VIT D LEVELS AND ECG CHANGES 
Risk factors No. of cases with Vit D level ‘p’ 
I II III IV 
No % No % No % No % 
e) ECG 
LAD, LVH 
(23) 
WNL (17) 
 
20 
3 
 
87 
17.6 
 
- 
3 
 
- 
17.6 
 
2 
6 
 
8.7 
35.3 
 
1 
5 
 
4.3 
29.4 
 
0.0001 
Significant 
 
Percentage of  ECG changes were significantly higher in cases with low 
vit D concentration ( level I) 
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VITAMIN-D AND ECG CHANGE 
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TABLE 12: VIT-D AND SMOKING 
Risk factors No. of cases with Vit D level ‘p’ 
I II III IV 
No % No % No % No % 
a) Smoking 
among males 
Yes (27) 
No (2) 
 
 
16 
1 
 
 
59.3 
50 
 
 
2 
- 
 
 
7.4 
- 
 
 
5 
1 
 
 
18.5 
50 
 
 
4 
- 
 
 
14.8 
- 
 
0.665  
Not 
significant 
 
Smoking did not have any significant association in regard with vitamin-
D levels. 
 
 
 
 
 
65 
 
 
 
 
TABLE 13: VIT-D AND CONCENTRIC LVH 
Risk factors No. of cases with Vit D level ‘p’ 
I II III IV 
No % No % No % No % 
b) Echo 
Normal (21) 
Abnormal (19) 
 
4 
17 
 
19 
89.5 
 
3 
2 
 
14.3 
10.5 
 
8 
- 
 
38.1 
- 
 
6 
 
28.6 
- 
 
0.0001 
Significant 
 
Percentage of  abnormal echo were significantly higher in cases with low 
vit D concentration ( level I) 
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VITAMIN-D AND LEFT VENTRICULAR HYPERTROPHY 
 
 
 
 
 
 
 
 
 
 
 
0
2
4
6
8
10
12
14
16
18
level-I level-II level-III level-IV
LV hypertrophy
normal study
67 
 
 
 
 
 
 
 
TABLE 14: VIT-D AND DM 
Risk factors No. of cases with Vit d level ‘p’ 
I II III IV 
No % No % No % No % 
c) DM 
Yes (13) 
No ( 27) 
 
11 
12 
 
84.6 
44.4 
 
- 
3 
 
- 
11.1 
 
2 
6 
 
15.4 
22.2 
 
- 
6 
 
- 
22.2 
 
0.0389 
Significant 
 
Percentage of diabetic cases were significantly higher in cases with low 
levels of vitamin-D. 
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 VITAMIN-D AND DIABETIC STATUS 
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TABLE 15: VIT D LEVELS AND B.P 
Vit D level SBP DBP 
Mean SD Mean SD 
I 176.26 10.9 101.0 8.5 
II 153.33 3.46 96 5.29 
III 147 3.7 88.75 4.1 
IV 142 2.5 84.33 4.8 
‘p’ 0.0001 
 significant 
0.0001 
  significant 
 
 In the hypertensive cases, there was significant association between B.P 
values and vit D levels ( p < 0.05). 
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 VITAMIN-D AND BLOOD PRESSURE 
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DISCUSSION 
                Hypertension is one of the leading causes of morbidity and mortality 
in both developing and developed countries, which is usually found incidentally 
by healthcare professionals during a routine checkup14. 
                                          
                                   Several potential mechanisms can explain the association 
of vitamin D deficiency with higher BP. Although the relationship between 
circulating levels of vitamin D and renin activity linkage was previously 
suggested in essential clinical hypertension studies65 , it has just recently been 
demonstrated that 1.25(OH)2-D directly modulates the renin–angiotensin 
system 66. Vitamin D deficiency is involved in secondary 
Hyperparathyroidism, and parathyroid hormone has been proved to have 
unfavourable cardiovascular effects, promoting arterial hypertension, left 
ventricular hypertrophy and cardiac fibrosis 67. 
                     Other potential mechanisms could include the effects of vitamin D 
on the cells of the vessel wall, which include endothelial cells, vascular smooth 
muscle cells, and macrophages, all of which express the vitamin D receptor 
(VDR) as well as 1α-hydroxylase . Therefore an optimal level of circulating 
1,25(OH)D which is regulated by 25(OH)D concentrations, is thought to be 
crucial for a normal level of BP . Our results are in line with these mechanisms 
and burgaz et al68 indicate that men with vitamin D levels of <37.5 nmol/L have 
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a 3-fold increased risk for hypertension compared to men with normal levels 
(>75 nmol/L). 
                                        An inverse relationship between vitamin D and the 
renin angiotensin system (RAS) activity suggests that vitamin D may act as an 
endogenous inhibitor of the RAS . This association has also been observed in 
other studies69,70. ( formann et al). 
 
                                       The authors of the Health Professionals Follow-Up 
Study of 38 388 men concluded that the 25(OH)D concentration required for 
normal BP was at least 37.5 nmol/L71 (formann et al).An expert panel has 
recently recommended a target range for 25(OH)D concentrations of 75–100 
nmol L) (30–40 ng mL) to reduce chronic disease including hypertension72 
(souberbille et al).  In our study we included hypertensive patients and found 
out that their vitamin-D levels were definetly lower than the normotensive 
counterparts. 
The first human study to investigate the association, that an inverse 
association existed between vitamin-D and hypertension examined 10 
normotensive individuals, as well as 51 hypertensive individuals, on ambient 
diet and found out that  all 61 individuals, there was an inverse correlation 
between PRA and 1,25(OH)2D (r__0.65; P_0.001)73 (resnick et al). In our study 
around 85% of all hypertensive patients had vitamin –D level below the target 
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level  (< 75nmol/L).one study by Jaume Almirall et al74 showed 86%  of the 
hypertensive patients had vitamin-D level less than 62.5nmol/L. 
               In this study age , sex , physical features like BMI were all adjusted 
between normotensive and hypertensive group. There was no confounding 
factor as suggested by the ‘p’ value. Both groups random blood sugar and renal 
functions were also matched .  
                            However serum uric acid was found to be elevated in the 
hypertensive group as compared to normotensive  patients .Similar results of 
elevated levels of uric acid in hypertensive patients is well documented75 
(cannon et al). 
                      Likewise retinopathy, left ventricular hypertrophy on 
echocardiogram and electrocardiographic changes suggesting left axis deviation 
and left ventricular hypertrophy were seen in the hypertensive patients as 
compared to normotensive group.   
                          The mean age in this study is 59. We have not included patients 
above the age of 70 as Aging decreases the amount of 7-dehydrocholesterol 
produced in the skin by as much as 75% by the age of 70 years. Therefore, a 70 
year old person has approximately 25% of the capacity to produce 
cholecalciferol compared with a healthy young adult (Holick, et al. 1989)76. 
                                  We have divided the hypertensive group into four groups 
based on the vitamin-D level as level-I <37.5nmol/L, level –II 37.5nmol/l to 
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49.9nmol/L , level –III as 50nmol/L to 74.5nmol/L , and  level-IV 75nmol/L to 
100 nmol/L.  This type of division is similar to that of a study conducted by 
burgaz et al68 . 
                                     By dividing the patients into four groups we try to 
analyse whether any significance does really exists between decreasing  level of 
vitamin-D and variables like systolic BP , diastolic BP, age , sex , BMI, serum 
calcium , retinopathy, left ventricular hypertrophy and electrocardiographic 
changes. 
                   The mean vitamin-D level in male hypertensive was 45.7 and in 
females 49, which was statistically not significant. This is in contrast to study 
done by Ian H. de Boer et al in which they have shown that serum vitamin-D 
level was less in male subjects. 
                 The serum vitamin-D level was significantly lower in hypertensive 
subjects when compared with normotensive patients. The mean vitamin-D level 
in cases was 46.6 and in controls was 62.3. Observational studies strongly 
support an inverse association between plasma 25(OH)D levels and blood 
pressure and hypertension77 ( Hintzpeter B). 
                     The serum vitamin-D level was found to significantly associated 
with ECG changes like LAD, LVH and left ventricular hypertrophy. Two small 
clinical trials of hemodialysis patients have shown that treatment with activated 
vitamin D [1,25(OH)D or related analogs] may lead to regression of LVH, 
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suggesting a cardioprotective action 78,79 (park et al, kim et al) . Cardiac 
hypertrophy has been observed in the hearts of VDR knockout mice 80 (xiang et 
al). Activated vitamin D has been shown to downregulate proliferation and 
hypertrophy in cultured cardiomyocytes 81,82(wu et al , nibbelink et al). 
                                 
                                     In this study we found out the diabetic status of 
hypertensive patients and around 13 patients were found to have diabetes 
mellitus . we associated diabetes with various levels of vitamin-D , and found 
significant association. In a study done by Mathieu et83 al they found out that 
Vitamin D deficiency predisposes individuals to type 1 and type 2 diabetes, and 
receptors for its activated form-1alpha,25-dihydroxyvitamin D3-have been 
identified in both beta cells and immune cells. 
                
                      No statistical significance was observed between vitamin –D level 
and smoking  .  The same was observed in the study conducted by Annamari 
Kilkkinen84 et al were patients were classified based on their daily intake of 
nicotine level. 
 
                    In our study we analysed systolic and diastolic blood pressure as 
continuous variable and compared with various levels of vitamin-D. There was 
a significant association between vitamin –D level and both systolic and 
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diastolic blood pressure. This is in line with the study conducted by Jaume 
Almirall et al74 where the authors demonstrated significant association between 
vitamin-D and systolic and diastolic blood pressure. Also low 25(OH)-D 
levels were significantly and independently associated with a 6.6 mmHg 
increase in systolic BP (95% CI: 1.5–11.6) after controlling for the other 
variables in the study. 
               
                           Vitamin-D deficiency has been documented to have elevated 
rennin level as Resnick et al73 originally reported that plasma renin activity 
(PRA) and 1,25- dihydroxyvitamin D (1,25[OH]2D) were inversely correlated 
(r__0.65) among  61 individuals on an ambient diet. Several years later, 
Burgess et al85 reported a similar association in 10 hypertensives (r__0.76). 
Interestingly, in a randomized trial that documented a 14-mm Hg decrease in 
SBP with vitamin D supplementation compared with placebo, the authors also 
noted a trend toward a decrease in circulating angiotensin II (Ang II) levels 
(_13.1 pg/mL; P_0.14) relative to placebo86. 
 
                     Not only does vitamin-D has a inverse relation with hypertension 
but studies by Harald Dobnig et al have showed Independent Association of 
Low Serum 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D Levels With 
All-Cause and Cardiovascular Mortality ,studies by  Mark F. McCarty et al 
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showed  that Poor vitamin D status may contribute to high risk for insulin 
resistance, obesity, and cardiovascular disease in Asian Indians. 
 
 
     Although many studies by burgaz et al and various other authors have 
demonstrated a inverse relation between vitamin-D and hypertension , few 
studies like the one by formann et al have demonstrated no significant 
association between vitamin-D level and hypertension. As there are 
controversies , it is suggested to carry out prospective studies among vitamin-D 
deficient patients and follow them to ascertain the rate of incident hypertension 
to ascertain the truth. 
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Conclusion : 
• Hypovitaminosis D was found in 57.5% of hypertensive patients while 
only 10% of the normotensive subjects demonstrated low levels of 
vitamin-D. 
• An inverse relation exists between vitamin-D and essential hypertension. 
• Hypovitaminosis D was significantly associated with left ventricular 
hypertrophy. 
• While considering systolic and diastolic blood pressure as continuous 
variables significant association was found with low levels of vitamin-D 
• There is no correlation between serum vitamin-D level with age , gender, 
body mass index and smoking. 
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GLOSSARY 
 
UVB   : ULTRAVIOLET B 
25(OH)D : 25 HYDROXY VITAMIND 
OCP  : ORAL CONTRACEPTIVE PILL  
NACL : SODIUM CHLORIDE 
PRA  : PLASMA RENNIN ACTIVITY 
PAD            :PERIPHERAL ARTERIAL DISEASE 
CHF  :CONGESTIVE HEART FAILURE   
VDBP :VITAMIN D BINDING PROTEIN 
VDR  :VITAMIN D RECEPTOR 
PTH  :PARATHYROID HORMONE 
MS  :MULTIPLE SCLEROSIS 
RA  :RHEUMATOID ARTHRITIS 
DM  :DIABETES MELLITUS 
IBD  :INFLAMMATORY BOWEL DISEASE 
CVD  :CARDIOVASCULAR DISEASE 
RAS  :RENIN ANGIOTENSIN SYSTEM 
CREB :C AMP RESPONSE ELEMENT BINDING PROTEIN 
SD  :STANDARD DEVIATION 
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SBP  :SYSTOLIC BLOOD PRESSURE 
DBP  :DIASTOLIC BLOOD PRESSURE 
ECG  :ELECTROCARDIOGRAPHY 
ECHO :ECHOCARDIOGRAM 
CAD  :CORONARY ARTERY DISEASE 
LVH  :LEFT VENTRICULAR HYPERTROPHY 
BP  :BLOOD PRESSURE 
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                                                                            PROFORMA 
 
 
NAME       :                                                                                 IP NO     : 
 
AGE/SEX   :                                                                                 WEIGHT:           HEIGHT:             
BMI: 
  
SMOKER:                                                                                   PREVIOUS H/O OF CAD: 
ALCOHOLIC:                                                                              HYPERTENSIVE: 
POST MENOPAUSAL:                                                              DIABETIC: 
 
TREATMENT H/O: 
 
General examination: 
Vitals:    pulse:    BP:                    right              left 
   Ul: 
   Ll: 
Resp rate: 
System examination: 
Cvs: 
 
Rs: 
 
Abdomen: 
Cns: 
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BLOOD INVESTIGATIONS:                                                                
UREA: 
SUGAR: 
CREATININE: 
SERUM ELECTROLYTES: 
 
SERUM PROTEINS: 
 
SERUM VITAMIN D: 
ECG : 
 
Echo: 
 
 
DIAGNOSIS: 
 
 
 
TREATMENT: 
 
 
 
 
 
 
 
 
1 
 
 
S.No  AGE 
 
SEX HT WT  BMI SMO S.B.P D.B.P UREA SR.CR CA PHOSP ALB CORR.CA    ECG    ECHO 
VIT-
D 
sr 
uric retino DM RBS 
1 31 M 1.58 60 24.035 Y 190 100 18 0.9 7.8 5 4.8 7.16 LAD,LVH CONC.LVH 30.1 5.3 I YES 218 
2 61 M 1.59 70 27.689 Y 170 90 26 1 7.1 3.4 4 7.1 LAD,LVH CONC.LVH 33.3 4.9 II NO 88 
3 55 F 1.48 59 26.936 N 160 100 34 1.2 7.1 3.3 3.2 7.74 LAD,LVH CONC.LVH 32.8 6.2 NO NO 110 
4 68 M 1.62 70 26.673 Y 180 110 30 1.2 7.2 3.3 3.3 7.76 WNL NORMAL 34.9 5.4 III NO 124 
5 42 M 1.64 69 25.654 Y 150 90 18 1.1 8.5 2.8 4 8.5 WNL NORMAL 67.9 3.8 III YES 98 
6 61 M 1.65 70 25.712 N 170 90 32 1 7.9 3.9 3 8.7 LAD,LVH CONC.LVH 28.2 8.6 IV YES 135 
7 63 M 1.66 78 28.306 Y 150 90 23 0.9 7.2 5 4 7.2 WNL NORMAL 49.9 5.4 I NO 154 
8 56 M 1.75 67 21.878 Y 140 80 39 1.2 7.7 5.6 3.8 7.86 LAD,LVH NORMAL 70 5.5 NO NO 122 
9 42 M 1.66 66 23.951 Y 140 90 18 1.3 8 4 3.5 8.4 WNL NORMAL 88.5 4.8 III NO 112 
10 71 M 1.7 66 22.837 Y 150 90 23 1.2 7.6 3.7 3.4 8.08 WNL NORMAL 50.5 6.9 I NO 98 
11 50 M 1.72 77 26.028 Y 170 100 42 1.9 7 2.8 3 7.8 LAD,LVH CONC.LVH 29.2 8.1 IV YES 256 
12 65 M 1.74 70 23.121 y 200 120 24 1.1 7 4 3.5 7.4 LAD,LVH CONC.LVH 31 6.8 III YES 309 
13 45 M 1.65 56 20.569 y 170 100 18 1 7 2.5 3.8 7.16 LAD,LVH CONC.LVH 24.8 7.3 IV NO 95 
14 55 F 1.59 78 30.853 N 180 90 20 1.2 7.2 3.2 3.6 7.52 WNL NORMAL 37.4 6.5 II NO 93 
15 60 F 1.55 67 27.888 N 150 90 26 1.3 7.6 4 3.2 8.24 WNL NORMAL 68.9 5.2 I NO 132 
16 71 F 1.58 54 21.631 N 140 80 38 1.1 8.4 3.7 3 9.2 LAD  NORMAL 78.4 4.5 III NO 116 
17 65 M 1.66 68 24.677 Y 170 100 41 1.3 7.4 4 3.6 7.72 LAD CONC.LVH 29.3 8.5 IV YES 287 
18 61 M 1.59 66 26.107 N 146 86 34 1.1 7.8 3 3.5 8.2 LAD,LVH NORMAL 67.3 4.6 NO NO 156 
19 52 M 1.63 77 28.981 Y 144 88 27 1 8 4 3.5 8.4 WNL NORMAL 79.8 3.3 NO NO 133 
20 74 M 1.58 56 22.432 Y 160 100 25 1.3 7.8 2.3 3.7 8.04 WNL CONC.LVH 40.8 5.5 I NO 129 
21 56 M 1.61 78 30.091 Y 184 104 25 1 7.3 4.8 3.7 7.54 WNL NORMAL 34.2 4.6 II NO 132 
22 65 M 1.64 78 29.001 Y 170 100 18 1.3 7.3 4.9 4 7.3 LAD,LVH CONC.LVH 28.9 7.4 III YES 243 
23 50 M 1.58 66 26.438 Y 170 90 23 1.1 7.4 3.9 3.3 7.96 LAD,LVH CONC.LVH 29.6 6.9 II YES 254 
24 61 F 1.54 55 23.191 N 160 100 21 1.2 7.7 4.5 3.2 8.34 LAD,LVH NORMAL 34.4 4.4 IV YES 265 
25 66 F 1.51 59 25.876 N 146 88 31 1.2 7.1 3 3.3 7.66 WNL NORMAL 78 5.4 NO NO 122 
26 60 F 1.58 64 25.637 N 190 110 30 1.1 7.2 4.1 3.5 7.6 LAD,LVH CONC.LVH 31.2 6.9 NO NO 77 
27 42 F 1.54 59 24.878 N 150 94 34 1.4 7.3 3.8 3.8 7.46 WNL NORMAL 59.6 5.4 NO NO 85 
28 60 M 1.61 66 25.462 Y 190 110 18 0.8 7 4.5 3.7 7.24 LAD,LVH CONC.LVH 29.3 7.6 II NO 94 
29 61 M 1.62 76 28.959 Y 142 90 33 1 8.6 3.6 3.5 9 WNL NORMAL 80 3.5 NO NO 113 
2 
 
30 65 M 1.66 78 28.306 Y 180 100 28 1.2 7 4.5 3.9 7.08 LAD,LVH CONC.LVH 20.8 7.3 IV YES 214 
31 50 F 1.58 70 28.04 N 170 90 34 1.4 7.1 3.7 3 7.9 LAD CONC.LVH 33.5 5.9 III YES 276 
32 70 M 1.62 56 21.338 Y 140 80 31 1 7.4 4 3.1 8.12 WNL NORMAL 72.9 6.4 I NO 99 
33 60 M 1.6 77 30.078 Y 170 110 32 1.5 7.1 3.8 3.2 7.74 LAD,LVH NORMAL 34.3 7.5 II YES 198 
34 57 F 1.55 56 23.309 N 156 98 22 1 7.1 4.1 3.5 7.5 WNL NORMAL 49.5 6.4 NO NO 87 
35 59 M 1.65 59 21.671 Y 180 110 32 1.2 7 4 3.4 7.48 LAD NORMAL 32.5 5.9 NO NO 98 
36 67 M  1.66 54 19.596 Y 146 90 21 1 7.4 4 3.6 7.72 WNL NORMAL 57.6 6.3 II YES 213 
37 56 F 1.56 51 20.957 N 170 100 23 1.5 7.7 3.2 3 8.5 LAD,LVH CONC.LVH 34.9 7.4 II NO 86 
38 65 M 1.69 56 19.607 Y 144 90 27 1.2 8.3 2.8 3.6 8.62 WNL NORMAL 88.9 3.9 IV NO 73 
39 77 M 1.65 59 21.671 Y 180 110 34 1.3 7.3 5.2 3.3 7.86 LAD,LVH CONC.LVH 28.9 6.6 NO NO 76 
40 66 M 1.78 76 23.987 Y 160 90 33 1.2 7.1 4.9 3.7 7.34 LAD,LVH CONC.LVH 30.5 5.4 NO NO 94 
41 56 M   1.69 78 27.31 N 130 80 32 1.1 8.2 3.8 3.5 8.6 WNL NORMAL 73.4 3.5 NO NO 88 
42 67 M  1.7 67 23.183 Y 120 70 24 1.4 8.5 2.5 3.7 8.74 WNL NORMAL 68.6 4.4 NO NO 110 
43 57 M 1.67 69 24.741 Y 110 70 32 1.3 7.9 2.8 3.6 8.22 WNL NORMAL 59.9 3.9 NO NO 109 
44 60 M 1.59 70 27.689 N 120 80 29 1.3 7.8 3 3.5 8.2 WNL NORMAL 69.3 3.6 NO NO 75 
45 59 M 1.67 79 28.327 Y 110 80 36 1.5 8.5 2.9 3.2 9.14 WNL NORMAL 89.8 4.6 NO NO 87 
46 65 F 1.55 66 27.471 N 110 70 28 1.1 8.1 2.2 3.6 8.42 LAD NORMAL 61.1 4.9 NO NO 98 
47 54 F 1.57 77 31.239 N 110 70 27 1.2 7.9 2.9 3.8 8.06 WNL NORMAL 48.8 4.8 NO YES 234 
48 67 F 1.59 55 21.755 N 110 80 33 1.1 7.8 2.8 3.1 8.52 WNL NORMAL 72.2 5.3 NO NO 98 
49 71 F 1.6 68 26.563 N 120 80 28 1.2 7.7 3.1 3.8 7.86 WNL NORMAL 90 5.8 NO NO 87 
50 56 F 1.62 56 21.338 N 110 70 33 1.4 8.1 4.4 3.1 8.82 WNL NORMAL 30.2 5.4 NO YES 198 
51 65 F 1.64 76 28.257 N 120 80 37 1.2 7.9 2.8 3.2 8.54 WNL NORMAL 78.9 5 NO NO 88 
52 67 M 1.67 65 23.307 Y 110 70 28 1.5 8.1 3.6 3.7 8.34 WNL NORMAL 39.9 4.7 NO YES 254 
53 69 M 1.71 67 22.913 Y 120 80 33 1.1 7.8 3.7 4 7.8 WNL NORMAL 57.9 5.9 NO NO 98 
54 65 M 1.69 67 23.459 Y 110 80 31 1.3 8 2.9 3.2 8.64 WNL NORMAL 70.2 4.3 NO NO 78 
55 70 M 1.76 87 28.086 Y 120 70 28 1.2 7.7 3.9 3.5 8.1 WNL NORMAL 45.7 4.8 NO YES 190 
56 55 M 1.69 77 26.96 Y 110 70 33 1.2 8.5 2.5 3.1 9.22 WNL NORMAL 69.8 5.4 NO NO 98 
57 65 M 1.76 65 20.984 Y 120 80 36 1.3 7.2 3.9 3 8 WNL NORMAL 59 5.4 NO NO 89 
58 67 M 1.68 76 26.927 N 110 70 27 1.2 7.9 2.9 2.7 8.94 WNL NORMAL 87 5.8 NO NO 75 
59 57 M 1.72 69 23.323 Y 120 70 28 1.8 8.1 3.9 4.1 8.02 WNL NORMAL 49.9 4.3 NO YES 178 
60 67 M 1.67 71 25.458 Y 110 80 32 1.1 7.8 5 3.9 7.88 WNL NORMAL 24.9 6.4 NO YES 278 
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